← 홈

Antibody · 고형암 (전체)

399개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 399개
AntibodySHOTFDACuratedFDABiologicMerckvedotin plus pembrolizumab …Approved

pembrolizumab (Keytruda)

Multiple solid tumors · PD-1

#PD-1#Antibody#Approved#FDA승인#바이오모아추천+5
효능 ORR 100%임상시험 1334상태 APPROVED
AntibodyHotEli LillyreleaseApproved

Cetuximab (Cetuximab)

Locally Recurrent Skin Squamous Cell Carcinoma; Metastatic Skin Squamous Cell Carcinoma · Head and Neck Cancer

#HeadandNeckCancer#Antibody#Approved#인기#항체+5
효능 ORR 100%임상시험 757상태 RECRUITING
AntibodyHotRochederuxtecan (Dato-DXd, Datro…Approved

trastuzumab (Herceptin)

Non Small Cell Lung Cancer; Colorectal Cancer · Metastatic Salivary Gland Carcinoma

#MetastaticSalivaryGlandCarcinoma#Antibody#Approved#인기#항체+5
효능 ORR 91.8%임상시험 676상태 RECRUITING
AntibodyHotRochePhase 3

atezolizumab (Tecentriq)

Advanced Solid Tumor · Thoracic Neoplasms, Lung Diseases, Small

#ThoracicNeoplasmsLungDiseasesSma#Antibody#Phase3#인기#항체+5
효능 ORR 95%임상시험 648상태 RECRUITING
AntibodyAHotBristol Myers SquibbdeliveryPhase 3

Ipilimumab (Ipilimumab)

Advanced Hepatocellular Carcinoma (HCC) · HER2

#HER2#Antibody#Phase3#인기#항체+5
효능 ORR 75%임상시험 413상태 ACTIVE
AntibodyAHotAstraZenecaderuxtecan 3Phase 3

Tremelimumab (Tremelimumab)

Hepatocellular Carcinoma · Muscle Invasive Bladder Cancer

#MuscleInvasiveBladderCancer#Antibody#Phase3#인기#항체+5
효능 ORR 84.6%임상시험 181상태 RECRUITING
AntibodyAHotEli Lilly-linkersPhase 2

EGFR inhibitor (Cetuximab, Cetuximab (EGFR inhibitor))

Advanced Solid Tumor; NSCLC · EGFR

#EGFR#Antibody#Phase2#인기#항체+5
효능 ORR 70.6%임상시험 166상태 ACTIVE
AntibodyCHotAstraZenecaPhase 2

durvalumab + tremelimumab (STRIDE, STRIDE (durvalumab + tremelimumab))

Advanced Unresectable Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#인기#항체+5
효능 ORR 37.4%임상시험 118상태 RECRUITING
AntibodyAHotRochePhase 3

Obinutuzumab (Obinutuzumab)

Breast Adenocarcinoma; Metastatic Breast Carcinoma · B-cell Lymphoma

#B-cellLymphoma#Antibody#Phase3#인기#항체+5
효능 ORR 100%임상시험 114상태 RECRUITING
AntibodyAHotMerckvedotin plus pembrolizumab …Phase 2

pembrolizumab (KEYTRUDA®, KEYTRUDA® (pembrolizumab))

Solid Tumors · Solid Tumor, Adult

#SolidTumorAdult#Antibody#Phase2#인기#항체+5
효능 ORR 93.5%임상시험 111상태 RECRUITING
AntibodyBHotBeiGeneVedotin, Tislelizumab, and …Phase 1

BGB-A317 (Tislelizumab, Tislelizumab (BGB-A317))

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase1#인기#항체+5
효능 ORR 68.3%임상시험 105상태 RECRUITING
AntibodyCHotRochederuxtecan plus fluoropyrim…Phase 2

trastuzumab (Herceptin, FLOT, 5-FU, leucovorin, docetaxel, oxaliplatin, 5-FU, leucovorin, docetaxel, oxaliplatin (FLOT), trastuzumab)

Adenocarcinoma of the Gastroesophageal Junction; Adenocarcinoma of the Stomach · Adenocarcinoma of the Gastroesophageal J

#AdenocarcinomaoftheGastroesophag#Antibody#Phase2#인기#항체+5
효능 ORR 61%임상시험 100상태 ACTIVE
AntibodyCBeiGeneVedotin, Tislelizumab, and …Phase 2

Tislelizumab (Tislelizumab)

Locally Recurrent Colorectal Cancer · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase2#인기#항체+5
효능 ORR 37.1%임상시험 96상태 RECRUITING
AntibodyCInnoventvedotin (an HER2-targeted a…Phase 3

Sintilimab (Sintilimab)

Advanced Hepatocellular Carcinoma (HCC) · HER2

#HER2#Antibody#Phase3#인기#항체+5
임상시험 95상태 RECRUITING
AntibodyARochePhase 3

atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody)

Carcinoma, Non-Squamous Non-Small Cell Lung · PD-L1

#PD-L1#Antibody#Phase3#인기#항체+5
효능 ORR 76.7%임상시험 88상태 ACTIVE
AntibodyCEli Lilly and CompanyDeruxtecan]Phase 3

Ramucirumab (Ramucirumab)

Advanced Esophageal Adenocarcinoma; Advanced Gastric Adenocarcinoma · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase3#인기#항체+5
효능 ORR 40%임상시험 86상태 RECRUITING
AntibodyCRegeneronPhase 2

Cemiplimab (Cemiplimab)

Breast Neoplasms; Breast Cancer · Solid Tumor

#SolidTumor#Antibody#Phase2#인기#항체+5
효능 ORR 44%임상시험 84상태 RECRUITING
AntibodyAAmgenPhase 3

Panitumumab (Panitumumab)

Colorectal Cancer; Resectable Colorectal Carcinoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase3#인기#항체+5
효능 ORR 77.3%임상시험 83상태 RECRUITING
AntibodyCJiangsu HengruiPhase 2

Camrelizumab (Camrelizumab)

Advanced Hepatocellular Carcinoma (HCC) · HER2

#HER2#Antibody#Phase2#인기#항체+5
임상시험 78상태 RECRUITING
AntibodyBristol Myers SquibbPhase 2

nivolumab (Opdivo, Nivolumab & Ipilimumab)

Carcinoma, Renal Cell; Clear-cell Metastatic Renal Cell Carcinoma · Prostate Cancer

#ProstateCancer#Antibody#Phase2#인기#항체+5
효능 ORR 61.3%임상시험 70상태 ACTIVE

1 / 20 페이지

← 이전다음 →